Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-23

Very good news to start the week. "DMX-200 is performing better than placebo..."

It would be interesting to see the data - ie. just what is the actual statistical difference between DMX-200 and placebo? However, the IDMC has recommended that the trial continue unchanged, so they must be satisfied with the result.

I look forward to the "second interim analysis point" which will again look at proteinurea, but it will also look at kidney function - and that will be critically important. After all - it's actual kidney function that will count here.

So - more waiting - but this first interim analysis is based on data from 72 patients, so we can be pretty confident that DMX-200 is shaping up as hoped. Also fabulous to see further confirmation of the excellent safety profile for DMX-200 - "no safety concerns."

Cheers

Dave